PHARMAQ appoints new board after sale to Permira Published: 04 June, 2013
On Friday 31st May 2013 the sale of PHARMAQ to Permira funds was completed. PHARMAQ is recognised as a leading pharmaceutical company specialising in aquaculture.
At the end of March, the shareholders of PHARMAQ entered into an agreement with the Permira funds concerning the sale of all shares of PHARMAQ Holding.
All conditions in the agreement were fulfilled and the transaction was completed on the 31st May 2013. PHARMAQ’s management and employees continue to hold a significant stake in the company.
Permira is a European private equity firm with global reach. Under its new owners, PHARMAQ intends to continue to operate in the same innovative and dynamic way as before with an aim of being the undisputed global leader within aquatic animal health.
Following the change in ownership, a new board of directors was elected at an extraordinary general assembly on Friday.
“We are very pleased to have a new owner and an experienced and professional board in place that will strengthen the position of PHARMAQ as a leading provider of pharmaceutical products to the global fish farming industry. The new board provides complementary knowledge to our team,” said Morten Kr. Nordstad, CEO of PHARMAQ.
The new board of directors is:
Svein Aaser, chairman of the board (pictured)
Kjell Bjordal, former head of Cermaq´s feed division EWOS
Ola Nordquist, head of the Nordic office – Permira
Dr. Erich Hunziker, former CFO of the Roche Group
Mubasher Sheikh, head of healthcare – Permira
Kjetil Fyrand, employee representative
Morten Nilsen, employee representative